Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
J&J deepens TB drug commitment
by Lisa M. Jarvis
August 28, 2017
| A version of this story appeared in
Volume 95, Issue 34
Johnson & Johnson has teamed with India’s Institute of Microbial Technology (IMTECH) to develop new treatments for tuberculosis. The goal is safer, more effective, all-oral treatments for multi-drug-resistant TB, as well as TB drugs with novel mechanisms for all people with TB. Scientists from J&J and IMTECH will work together to tackle TB, which in 2015 killed nearly 500,000 people in India. In late 2012, J&J received approval for Sirturo, the first new TB treatment in 40 years.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X